摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(tert-butyl)piperidin-2-one | 65970-69-6

中文名称
——
中文别名
——
英文名称
5-(tert-butyl)piperidin-2-one
英文别名
(+/-)-5-tert-Butyl-1-aza-2-cyclohexanon;5-t-Butyl-1-azacyclohexanon-2;5-Tert-butylpiperidin-2-one
5-(tert-butyl)piperidin-2-one化学式
CAS
65970-69-6
化学式
C9H17NO
mdl
MFCD24560378
分子量
155.24
InChiKey
LANVXPAJQOJQFF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.888
  • 拓扑面积:
    29.1
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

  • 作为产物:
    参考文献:
    名称:
    七元环烯醇化物反应中高非对映选择性的起源
    摘要:
    手性七元环烯醇化物的非对映选择性反应已被系统研究。发现对于具有各种取代基模式的ε-内酰胺、ε-内酯和环庚酮来说,非对映选择性是普遍的。计算研究提供了对非对映选择性起源的深入了解。提出了预测七元环烯醇化物烷基化立体化学的模型。
    DOI:
    10.1002/anie.202114183
点击查看最新优质反应信息

文献信息

  • 6.5 -PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS
    申请人:Bao Jianming
    公开号:US20100197724A1
    公开(公告)日:2010-08-05
    The present invention is directed to certain hydroxymethyl ether hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, LUTS, depression, and anxiety.
    本发明涉及某些羟甲基醚羟异吲哚化合物,其可用作神经激肽-1(NK-1)受体拮抗剂,以及缓激肽和特别是P物质的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方,以及这些化合物及其配方在治疗某些疾病,包括呕吐、尿失禁、下尿路症状、抑郁症和焦虑症中的用途。
  • NEW COMPOUNDS
    申请人:PROXIMAGEN LIMITED
    公开号:US20160024080A1
    公开(公告)日:2016-01-28
    The compound of formula (I) are inhibitors of SSAO activity (Formula (I)) wherein the terms Y, Z, W, R 1 and R 2 are defined in the claims.
    化合物的化学式(I)是SSAO活性的抑制剂(化学式(I)),其中术语Y、Z、W、R1和R2在专利权要求中有定义。
  • TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
    申请人:Babu Srinivasan
    公开号:US20110201593A1
    公开(公告)日:2011-08-18
    The invention provides novel compounds of formula I having the general formula: wherein R 1 , R 2 , R 3 , X and Y are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders.
    本发明提供了具有以下一般式的新化合物I: 其中R1、R2、R3、X和Y如本文所述。因此,这些化合物可以在药学上可接受的组合物中提供,并用于治疗免疫或过度增生性疾病。
  • TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS
    申请人:BROWN James
    公开号:US20130158034A1
    公开(公告)日:2013-06-20
    Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    式I的化合物是TRPM8拮抗剂,对于治疗许多TRPM8介导的疾病和症状有用,并可用于制备治疗此类疾病和症状的药物和制剂。此类疾病的例子包括但不限于偏头痛和神经病性疼痛。式I的化合物具有以下结构:其中变量的定义在此提供。
  • CHROMAN DERIVATIVES AS TRPM8 INHIBITORS
    申请人:AMGEN INC.
    公开号:US20150031668A1
    公开(公告)日:2015-01-29
    Chroman compounds and derivatives of Formula I are useful inhibitors of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    公式I的铬化合物和衍生物是TRPM8的有用抑制剂。这些化合物可用于治疗许多TRPM8介导的疾病和情况,并可用于制备用于治疗这些疾病和情况的药物和制剂。这些疾病的例子包括但不限于偏头痛和神经病性疼痛。公式I的化合物具有以下结构:其中变量的定义在此提供。
查看更多